omniture
logo
Search
LISCURE BIOSCIENCES CO. LTD.
Media Room

Latest News

rss

LISCure Expands Global Partnerships for BBB Shuttle Platform 'ExoPN-101'; Signs Fourth MTA with Leading Pharma Partner

SEOUL, South Korea, Nov. 13, 2025 /PRNewswire/ -- LISCure Biosciences ("LISCure"), a biotechnology ...

2025-11-13 21:00 823

LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)

SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences  ("...

2025-11-10 20:00 804

LISCure BioSciences Secures World's First Approval for "Joint Health Probiotic" as Recognized Health Functional Ingredient

SEOUL, South Korea, Oct. 22, 2025 /PRNewswire/ -- LISCure BioSciences ("LISCure") announced that it...

2025-10-22 14:28 962

LISCure BioSciences Secures World's First FDA NDI notification for Hair Health Probiotic Mobiome®

SEOUL, South Korea, Sept. 9, 2025 /PRNewswire/ -- LISCure BioSciences ("LISCure") today announced t...

2025-09-09 13:41 1240

LISCure Biosciences Secures World's First Regulatory Approval for Hair Health Probiotic as an functional Ingredient

SEONGNAM, South Korea, March 20, 2025 /PRNewswire/ -- LISCure Biosciences Inc. ("LISCure") announce...

2025-03-20 21:00 2048

LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC)

* Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported ...

2024-03-29 21:00 3400

Celltrion and LISCure Biosciences announce strategic collaboration to develop novel microbiome treatment for Parkinson's disease

* Co-research and co-development of novel microbiome therapeutics * Discovery of new candidates ...

2023-02-20 22:00 2585

LISCure's Phase 2 Drug Candidate Granted Orphan Drug Designation (ODD) from US FDA

First Orphan Drug Designation (ODD) in the field of microbiome-based treatment for metabolic diseas...

2022-12-08 22:00 2396

LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022

The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and infl...

2022-10-28 21:00 2424

LISCure Biosciences Announces Research Collaboration with The Scripps Research Institute for Immuno-Oncology

SEOUL, South Korea, Feb. 3, 2022 /PRNewswire/ -- LISCure Biosciences ("LISCure") announced that it ...

2022-02-03 22:00 2113

LISCure Biosciences announces research collaboration with Mayo Clinic for rare liver diseases

SEOUL, South Korea, Jan. 6, 2022 /PRNewswire/ -- LISCure Biosciences Inc., a leading biotech focuse...

2022-01-06 22:00 1944

LISCure Biosciences received clinical approval for two microbiome programs targeting autoimmune disease and NASH

SEOUL, South Korea, Sept. 30, 2021 /PRNewswire/ -- LISCure Biosciences ("LISCure") announced that i...

2021-09-30 21:00 1722

LISCure Biosciences Announces Know-How License Agreement and Stock Purchase Agreement with Mayo Clinic

SEOUL, South Korea, Aug. 1, 2021 /PRNewswire/ -- LISCure Biosciences, Inc. ("LISCure") has entered ...

2021-08-02 11:11 1606

LISCure Biosciences Successfully Raises $21 million in Series B Funding

SEOUL, South Korea, Feb. 26, 2021 /PRNewswire/ -- On February 25th, 2021, LISCure Biosciences Inc.,...

2021-02-26 22:00 3626
LISCure Biosciences Successfully Raises $21 million in Series B Funding